AC Immune has entered into a worldwide exclusive license agreement and research collaboration with Janssen Pharmaceuticals, to develop and commercialize therapeutic anti-Tau vaccines for the treatment of Alzheimer’s disease and potentially other tauopathies.
Searching for more deal information? Current Partnering offers the following options:
|
Janssen Research & Development, an affiliate of Janssen Pharmaceuticals, will further develop the lead therapeutic vaccine, ACI-35, that is currently in a phase Ib clinical trial in Alzheimer’s patients.
ACI-35 is an active therapeutic vaccine stimulating the patient's immune system to produce a polyclonal antibody response against phosphorylated Tau protein.
AC Immune will receive an upfront payment and is eligible to receive research, development and commercialization milestone payments potentially totaling up to USD 509 million (CHF 500 million) for Alzheimer´s disease and a potential second indication outside of Alzheimer´s disease.
Additionally, the company is eligible to receive tiered royalties on net sales for any approved products resulting from the collaboration.
AC Immune and Janssen will co-develop ACI-35 through phase Ib completion.
As of phase II and onward, Janssen will assume responsibility for the clinical development, manufacturing and commercialization of ACI-35.
Additionally, the two companies have entered a three year joint research collaboration to further characterize and develop novel vaccine therapies for the treatment of tauopathies.
For further deal information visit Current Agreements (subscription required)
Related
Scorecard: Top partnering deals by value in 2014
View: Top pharmaceutical companies
View: Top biotech companies
Report: Top 50 Big Pharma Partnering and M&A Deal Trends
Report: Top 50 Big Biotech Partnering and M&A Deal Trends
